Literature DB >> 26614398

Concordance study between one-step nucleic acid amplification and morphologic techniques to detect lymph node metastasis in papillary carcinoma of the thyroid.

Sofía del Carmen1, Sonia Gatius2, Guzmán Franch-Arcas1, José Antonio Baena2, Oscar Gonzalez3, Carlos Zafon3, Dolors Cuevas2, Joan Valls2, Angustias Pérez1, Mercedes Martinez1, Susana Ros2, Carmen García Macías1, Carmela Iglesias3, Xavier Matías-Guiu4, Enrique de Álava5.   

Abstract

Tumor resection in papillary thyroid carcinoma (PTC) is often accompanied by lymph node (LN) removal of the central and lateral cervical compartments. One-step nucleic acid amplification (OSNA) is a polymerase chain reaction-based technique that quantifies cytokeratin 19 (CK19) messenger RNA copies. Our aim is to assess the value of OSNA in detection of LN metastases in PTC, in comparison with imprints and microscopic analysis of formalin-fixed, paraffin-embedded (FFPE) tissue. A total of 387 LNs from 37 patients were studied. From each half LN, 2 imprints were taken and analyzed with hematoxylin and eosin (H&E) and CK19 immunostaining. One half of the LN was submitted to OSNA and one half to FFPE processing and H&E and CK19 staining. For concordance analysis, every single LN was considered as a case. A group of 11 cases with discordant results between OSNA and H&E/CK19 FFPE sections were subjected to additional FFPE serial sectioning and H&E and CK19 staining. We found a high degree of concordance between the assays used, with sensitivities ranging from 0.81 to 0.95, and specificities ranging from 0.87 and 0.98. OSNA allowed upstaging of patients from pN0 to pN1, in comparison with standard pathologic analysis. Identification of a metastatic LN with more than 15000 CK19 messenger RNA copies predicted the presence of a second LN with macrometastasis (<5000 copies). In summary, the study shows that OSNA application in sentinel or suspicious LN may be helpful in assessing nodal status in PTC patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymph node; Metastasis; OSNA; Papillary carcinoma; Thyroid

Mesh:

Substances:

Year:  2015        PMID: 26614398     DOI: 10.1016/j.humpath.2015.09.020

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  One-step nucleic acid amplification (OSNA): where do we go with it?

Authors:  Yasuhiro Tamaki
Journal:  Int J Clin Oncol       Date:  2016-08-22       Impact factor: 3.402

2.  Molecular Heterogeneity of Papillary Thyroid Cancer: Comparison of Primary Tumors and Synchronous Metastases in Regional Lymph Nodes by Mass Spectrometry Imaging.

Authors:  Marta Gawin; Agata Kurczyk; Ewa Stobiecka; Katarzyna Frątczak; Joanna Polańska; Monika Pietrowska; Piotr Widłak
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

3.  Endoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden.

Authors:  Iban Aldecoa; Carla Montironi; Nuria Planell; Maria Pellise; Gloria Fernandez-Esparrach; Angels Gines; Salvadora Delgado; Dulce Momblan; Leticia Moreira; Maria Lopez-Ceron; Natalia Rakislova; Graciela Martinez-Palli; Jaume Balust; Josep Antoni Bombi; Antonio de Lacy; Antoni Castells; Francesc Balaguer; Miriam Cuatrecasas
Journal:  Surg Endosc       Date:  2016-06-20       Impact factor: 4.584

4.  Detection of lymph node metastasis in lung cancer patients using a one-step nucleic acid amplification assay: a single-centre prospective study.

Authors:  María Escalante Pérez; María Teresa Hermida Romero; Begoña Otero Alén; Mónica Álvarez Martínez; Ricardo Fernández Prado; Mercedes de la Torre Bravos; Ángel Concha López
Journal:  J Transl Med       Date:  2019-07-22       Impact factor: 5.531

5.  Evaluation of accuracy of one-step nucleic acid amplification (OSNA) in diagnosis of lymph node metastases of papillary thyroid carcinoma. Diagnostic study.

Authors:  Fabio Medas; Pierpaolo Coni; Francesco Podda; Claudia Salaris; Federico Cappellacci; Gavino Faa; Pietro Giorgio Calò
Journal:  Ann Med Surg (Lond)       Date:  2019-08-21

6.  Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure.

Authors:  Josef Vodicka; Martin Pesta; Vlastimil Kulda; Katerina Houfkova; Bohuslava Vankova; Jakub Sebek; Martin Skala; Jakub Fichtl; Kristyna Prochazkova; Ondrej Topolcan
Journal:  Cells       Date:  2020-12-04       Impact factor: 6.600

7.  Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review.

Authors:  Enrique Trilla; Juan Morote; Mercè Cuadras; Jacques Planas; Ana Celma; Lucas Regis; Inés M de Torres; M Eugenia Semidey
Journal:  BMC Cancer       Date:  2022-04-02       Impact factor: 4.430

8.  One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective study.

Authors:  Kei Namba; Ken Suzawa; Kazuhiko Shien; Akihiro Miura; Yuta Takahashi; Shunsaku Miyauchi; Kota Araki; Kentaro Nakata; Shuta Tomida; Shin Tanaka; Kentaroh Miyoshi; Shinji Otani; Hiromasa Yamamoto; Mikio Okazaki; Seiichiro Sugimoto; Junichi Soh; Masaomi Yamane; Shinichi Toyooka
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.996

9.  Ultrastaging Using Ex Vivo Sentinel Lymph Node Mapping and One-Step Nucleic Acid Amplification (OSNA) in Gastric Cancer: Experiences of a European Center.

Authors:  Bruno Märkl; Bianca Grosser; Kerstin Bauer; Dmytro Vlasenko; Gerhard Schenkirsch; Andreas Probst; Bernadette Kriening
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

10.  The Diagnostic Accuracy of One-Step Nucleic Acid Amplification for Lymph Node Metastases of Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Xiaofei Wang; Xun Zheng; Jingqiang Zhu; Zhihui Li; Tao Wei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-04       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.